SuperworthLifevantage market cap LFVN
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $73.4M
- Highest close in our data
- $384.4M
- Sep 2012
Lifevantage is worth $73.4M at the close on Oct 23, 2026, at $5.86 a share.
That is down 33% over the last year and down 21% over five years.
Its highest close in our data was $384.4M in Sep 2012.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $73.4M | $53.1M | $125.8M | −5% |
| 2025 | $77.1M | $77.1M | $317M | −66% |
| 2024 | $223.6M | $71.8M | $223.6M | +193% |
| 2023 | $76.3M | $42M | $99.1M | +63% |
| 2022 | $46.8M | $44.3M | $86.7M | −44% |
| 2021 | $83.7M | $81.4M | $137.1M | −37% |
| 2020 | $132.9M | $132.9M | $235.2M | −39% |
| 2019 | $216.4M | $155M | $226.8M | +17% |
| 2018 | $184.2M | $50.9M | $200.8M | +172% |
| 2017 | $67.7M | $42.6M | $108.2M | −41% |
| 2016 | $114.6M | $107M | $213.6M | −14% |
| 2015 | $133.3M | $47.5M | $133.3M | +0% |
| 2014 | $133M | $115.8M | $167M | −20% |
| 2013 | $166M | $155.8M | $317.6M | −29% |
| 2012 | $235.2M | $135M | $384.4M | +66% |
| 2011 | $142M | $134M | $147M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Lifevantage's size, closest first, today.
| Company | Market cap |
|---|---|
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| ATNMActinium Pharmaceuticals | $47.8M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Lifevantage
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.